

Index

- Abnormal mitotic figures (AMF), 193–194, 200–201
- Abortion, 816–823
spontaneous, *see* Spontaneous abortion
triploid, 818, 820
- Abruptio placenta, 801
- Acanthosis, 189
- Acanthosis nigricans, 487, 491–492
- Acardiac fetus, 783
- Accessory lobe of placenta, 775, 776
- Accessory ovary, 472
- Acridine orange fluorescence, in cervix, 203
- Acrochordon, 63
- Actinomyces*
cytology of, 883–884
in endometrium, 315
- Actinomycosis
of cervix, 163
of fallopian tube, 418–419
of ovary, 475
pelvic, 474–475
- Adenoacanthoma, 348–349, 579–580
tubal, 429
- Adenoacanthosis, 327
- Adenocarcinoid, 700
- Adenocarcinoma
argyrophil cell, 354, 359
Bartholin's gland, 80
of cervix, 236–243, 889–890
clear cell, 121–127, 240, 353–354, 358, 587–589
endometrial, 893
endometrioid-type
in cervix, 238
in endometriosis, 534
in situ, 236
invasive, *see* specific sites
metastatic, *see* specific sites
minimal deviation, of cervix, 242
mucinous intestinal, 238, 240
with squamous differentiation, 348–351, 580
with squamous metaplasia, 348–350
tubal, 427–429
unclassifiable, 596–597
of ovary, 596–597
of vagina, 114
of vulva, 79–81
- Adenofibroma
of cervix, papillary, 170–171
of ovary
clear cell, 587
endometrioid, 578
mucinous, 574
serous, *see* Serous cystadenofibroma
of uterus, 394–396
- Adenoid cystic carcinoma, 80, 243
- Adenoid squamous carcinoma, 78
- Adenoma malignum, 242
- Adenomatoid mesothelioma, 402
- Adenomatoid tumor, 425–426, 548, 732
- Adenomatous hyperplasia, 323
- Adenomyoma, 171, 401–402, 425
- atypical polypoid, 307–309, 401–402
- Adenomyomatous polyp, 305
atypical, 341
- Adenomyosis, 401–402, 517
endometrial carcinoma and, 363
- Adenosarcoma
ovarian, 582–584
uterine, 394–398
mesenchymal components of, 396
- Adenosis
atypical, 134–135
vaginal, *see* Vaginal adenosis
- Adenosquamous carcinoma, 243–245, 350–351
- Adnexal torsion, 502–503
- Adnexal tumor of probably wolffian origin, 430–431, 463
- Adrenal gland tumors, metastatic to ovary, 760
- Adrenal rest tumors, 641
- Adrenal rests, 430, 473
- Adrenogenital syndrome, 20–21
- AFP, *see* Alpha-fetoprotein
- Albinism, 52
- Alcian blue stain, 240
- Allantoic duct remnant, 813
- Alpha-fetoprotein (AFP), 333–334, 670
germ cell tumors and, 678–679, 680
- 5-Alpha-reductase deficiency, 26
- Alveolar soft part sarcoma, 82, 117
- Amebiasis, ulceronecrotic, of cervix, 165
- Amenorrhea, 315, 896–897
- Amnion, squamous metaplasia of, 809
- Amnion nodosum, 809–811
- Amnionic bands, 811–812
- Amnionic infection, 784–789
- Amnionic rupture, early, 811–812
- Amylase
epithelial, 600
mesothelial, 546

- Amyloidosis, ovarian, 503
 Androblastoma, 625
 Androgen insensitivity syndrome, 24-26
 Androgens
 from fetal testis, 12-13
 maternal ingestion of, 21
 ovarian stroma and, 444
 to produce tumors in animals, 905, 914
 squamous cells and, 894
 Androstenedione
 in corpus luteum of menstruation, 455
 estrone from, 339, 491
 intrafollicular, 459
 in menopause, 466
 ovarian, 444
 by ovarian hilus cells, 461
 in polycystic ovarian disease, 498
 theca-derived, 451
 Aneuploidy
 in cervix, 198-200
 endometrial, 333
 Angiogenesis factor, 270
 Angiokeratoma, 59
 Angiomyxoma, aggressive, 62-63
 Angiosarcoma
 in ovary, 728
 in uterus, 403
 Animal tumor models, 899-917
 Annulate lamellae, ovarian, 445-446
 Anovulatory cycles, 299
 Antral follicles, 446, 447
 Apocrine glands, vulva, 37
 Apoplexia uteri, 286
 Appendiceal tumors, metastatic to ovary, 754-755
 Argyrophil cell adenocarcinoma, 354, 359
 Arias-Stella reaction, 137, 172, 240-241, 282, 298, 479, 524
 Arrhenoblastoma, 625
 Arteriosclerosis, hyperplastic, 806
 Arteritis, ovarian, 503
 Ascending infection, placental, 784-789
 Asherman's syndrome, 315-316
Aspergillus, 477
 Aspiration cytology, 893-894
 Ataxia telangiectasia, 471, 500
 Atherosclerosis, acute, 804-805
 Atretic follicles, 457-459
 Atrophic polyps, 306
 Atypia of repair, 158-159, 160, 199
 Auspitz sign, 52
 Autoimmune factors in endometriosis, 527
 Autoimmune oophoritis, 501-502
 of ovary, 589-596
 benign, 589-595
 low malignant potential (LMP), 595-596
 malignant, 595-596
 proliferating, 593-595
 of uterus, 308-309
 Breus' mole, 799-800
 Burkitt's lymphoma, 736-737
 Buschke-Lowenstein, giant condyloma of, 41
 Busulfan (Myleran), cellular changes secondary to, 891

 Call-Exner bodies, 446, 449, 610
Calymmatobacterium granulomatis, 46
 Cambium layer, 116
 Cancer, *see* Carcinoma
Candida albicans, in cervical smears, 882, 885
 Candidiasis
 with autoimmune oophoritis, 502
 of placenta, 785-788
 of vagina, 105, 502
 Canine ovarian tumors, 901
 Canine vulvular sarcoma, 916
 Carbon dioxide laser, 208-209
 Carcinoembryonic antigen (CEA), 198, 234, 333-334, 358-359, 480, 599-600
 Carcinogens, chemical, in animals
 o-aminotoluene, 907
 benzo[a]pyrene, 906-907, 912, 914
 bromocriptine, 911
 Carbowax, 1000, 915
 diethylstilbestrol, 904-905, 901-911;
 see also Diethylstilbestrol entries
 7,12-dimethylbenz[a]anthracene, 906-907, 912, 915
 N,N'-dimethyl-*N*-nitrosourea, 915
 fluorenyl derivatives, 912
 2-fluorenylacetamide, 905, 907
 3-methylcholanthrene, 906-907, 912, 915
 4-nitroquinoline-1-oxide, 912
 N-nitroso compounds, 912
 polyethylene glycol, 915
 procarbazine hydrochloride, 912
 triethylene melamine, 907
 7,8,12-trimethyl-benz[a]anthracene, 906
 urethane, 912
 Carcinoid syndrome, ovarian tumors associated with, 646
 Carcinoid tumors
 adenocarcinoid, 700
 cervical, 245-248
 granulosa cell tumor versus, 612
 insular, 696-698

 Bacterial cervicitis, 160-163
 Bacterial oophoritis, 473
 Bacterial vaginosis, 105
 Balanitis xerotica obliterans, 55
 Balbiani's vitelline body, 444, 445
 Barr bodies, 661
 Bartholin cysts, 57-58
 Bartholin glands, 37
 Bartholin's gland adenocarcinoma, 80
 Basal cell carcinoma, 79, 114
 Basal cell nevus syndrome, hereditary, 621
 Behçet's syndrome, 49
 11-Beta-hydroxylase defect, 21
 3-Beta-hydroxylase dehydrogenase deficiency, 23
 Bilharziasis, *see* Schistosomiasis
 Bilobate placenta, 775-776
 Biopsy techniques for processing, 927-928
 cervical cone, 927-929
 cervical punch, 927
 endometrial, *see* Endometrial biopsy
 ovarian, 928
 vaginal, 927
 vulvar, 927
 Biopsy punch, Kevorkian, 204, 207
 Bipartite placenta, 775-776
 Births, multiple, 784
 Bladder, *see* Urinary bladder
 Blastocyst, 1, 270, 769, 850
 Blastomycosis
 endometrial, 297
 ovarian, 477
 Bleeding, *see also* Hemorrhage
 breakthrough, 311
 dysfunctional uterine, 286, 299
 estrogen withdrawal, 299-302, 313
 menstrual, 276
 abnormal, 302-303
 postmenstrual, 307, 335-336, 384, 388, 395-396, 398, 609
 Blighted ovum, 853
 Blocking antibodies, 818
 Bone
 in endometriosis, 524
 in endometrium, 310
 in mesenchymal tumors of ovary, 730-731
 in ovary, 499
 Borderline malignancy, 569
 Bouin's fixative, 289, 926
 Bovine ovarian tumors, 900-901
 Breast carcinoma, metastatic
 of ovary, 747-748
 of placenta, 826
 of uterus, 357
 Breast tissue, ectopic, in vulva, 63
 Brenner tumor
 extraovarian, 541

- intestinal, 697
 metastatic to ovary, 755-758
 mucinous, 700-701
 of ovary, classified, 696
 Sertoli-Leydig cell tumor versus, 632
 struma ovarii, 701-703
 strumal, 701-703
 trabecular, 698-700
- Carcinoma**
 adenoid cystic, 80, 243
 adenosquamous
 of cervix, 243-245
 endometrial, 350-351
 animal studies of, 899, 902
 basal cell, 79, 114
 breast, *see* Breast carcinoma
 cervical, *see* Cervical carcinoma
 of cervical stump, 235
 clear cell, *see* Clear cell carcinoma
 dual primary
 of cervix, 245, 745
 of uterus, 356, 745
 embryonal, *see* Embryonal carcinoma
 endometrial, *see* Endometrial carcinoma
 endometrioid, *see* Endometrioid carcinoma
 in endometriosis, 534
 of fallopian tube, 744-745
 gastric, metastatic to ovary, 748-752
 glassy cell
 cervical, 244-245
 endometrial, 356
 hepatocellular, metastatic to ovary, 759
 intestinal, metastatic to ovary, 752-754
 invasive, *see* Invasive carcinoma
 islet cell, metastatic to ovary, 759
 mesonephric, 243
 microinvasive, of cervix, 218-224
 mixed epithelial, of cervix, 243-245
 mucinous, *see* Mucinous carcinoma
 mucoepidermoid, 245
 neuroendocrine, *see also* Carcinoid tumors
 argyrophil cell, 354, 359
 of cervix, 245-247
 ovarian, *see* Ovarian carcinoma
 in pregnancy, 235
 renal cell, metastatic to ovary, 759-760
 serous, *see* Serous carcinoma
 signet-ring cell, 748
 small cell, *see* Small cell carcinoma
 squamous, *see* Squamous carcinoma
 sweat gland, of vulva, 80-81
 undifferentiated, granulosa cell tumors versus, 612
 urethral, 87
 vaginal, *see* Vaginal carcinoma
- verrucous, 78-79, 114, 235-236
 vulvar, *see* Vulvar carcinoma
- Carcinoma in situ (CIS)**
 of cervix, 177-178
 of endometrium, 323
 of fallopian tube, 426-427
 of vagina, 111-112
- Carcinosarcoma**
 in endometriosis, 534
 of fallopian tube, 429
 of ovary, 584-585
 of uterus, 394, 400
- Cartilage**
 in cervix, 174
 in endometrium, 310
 in mesenchymal tumors
 of fallopian tube, 429
 of ovary, 585, 729-730
 of uterus, 396, 400
- Caruncles**, 86-87
- Cavernous hemangioma of vulva**, 59
- CEA**, *see* Carcinoembryonic antigen
- Cervical biopsy**, 203-208, 927
- Cervical cancer**, *see* Cervical carcinoma
- Cervical carcinoids**, 245-248
- Cervical carcinoma**, 218-247, 745
 adenocarcinoma, 236-243
 in situ, 236
 invasive, 236-242
 specific variants of, 242-243
 of cervical stump, 235
 cytologic changes secondary to radiation therapy for, 890, 891
 cytologic features of invasive, 887-890
 effects of radiation, 248-251
 invasive adenocarcinoma, 236-242
 behavior, 241
 differential diagnosis, 240-241
 microscopic appearance, 237-240
 treatment, 241-242
 invasive squamous, 224-235
 behavior, 233-235
 clinical aspects, 227
 differential diagnosis, 229-230
 gross features, 227-228
 immunohistochemistry, 230-232
 incidence and age distribution, 225-226
 microscopic features, 228-229
 modes of spread, 233
 pathogenesis, 226-227
 terminology and definitions, 224-225
 treatment, 233-235
 ultrastructure, 232-233
 metastatic tumors, to cervix, 247, 249
 microinvasive squamous, 218-224
 clinical aspects, 221
 frequency and age distribution, 221
- microscopic features and ultrastructure, 221-223
 terminology and definitions, 218-221
 treatment, 223-224
- mixed epithelial, 243-245
 adenosquamous, 243-245
 dual primary, 245
 glassy cell, 244-245
 mucoepidermoid, 245
 neuroendocrine, 245-246
 carcinoid, 245
 small cell, 245-248
 in pregnancy, 235
 rare tumors, 246-247
 verrucous, 235-236
- Cervical columnar epithelium**, 145-147
- Cervical condyloma**
 clinical features and natural history of, 184-186
 cytologic features, 883, 885-886
 differential diagnosis of, 193-195
 epidemiology and etiology of, 178-184
 immunohistochemistry of, 195-198
 management of, 210
 multifactorial pathogenesis of, 180
 pathologic features, 188-191
 ploidy level analysis, 198, 200
- Cervical cone biopsy**, 209-210, 927-929
- Cervical cytology**, 201-203, 876-878, 897; *see also* Gynecologic and obstetric specimens
- Cervical ectropion**, 129, 131-134
- Cervical endometriosis**, 172, 529
- Cervical erosion**, 149, 151
- Cervical fibrous polyp**, 167
- Cervical hyperkeratosis**, 159, 161
- Cervical intraepithelial neoplasia (CIN)**, 111, 178-210, 884-887
 clinical features and natural history of, 186-188
 DES and, 135, 183
 detection and diagnosis of, 201-208
 differential diagnosis of, 193-195
 epidemiologic risk factors for, 179
 epidemiology and etiology of, 178-184
 immunohistochemistry of, 195-198
 invasive carcinoma and, 226-227
 management of, 201-210
 pathologic features of, 191-193
 ploidy level analysis, 198, 200
 treatment of, 208-210
- Cervical parakeratosis**, 159, 161
- Cervical polyps**, 166-168
- Cervical schistosomiasis**, 165-166
- Cervical squamous epithelium**, 142-145
- Cervical stump, carcinoma of**, 235

- Cervicitis, 158, 881–884
 acute, 881
 bacterial, 160–163
 cryosurgery in, 891
 fungal, 165
 infectious, 160–166
 noninfectious, 159
 parasitic, 165
 protozoal, 165
 tuberculous, 163
 viral, 163–165
- Cervicovaginitis emphysematosa, 165
- Cervix
 adenocarcinoma of, 236–243, 889–890
 amebiasis of, 165
 anatomy and histology of, 141–156
 benign diseases of, 158–174
 benign neoplasms of, 170–172
 carcinoma of, *see* Cervical carcinoma
 cartilage in, 174
 choriocarcinoma of, 246–247
 endocervical hyperplasia, *see* Endocervical hyperplasia
 endocervical polyps, 166–168
 endometriosis, 529
 gross anatomy of, 141–142
 gross structural changes of, 128
 heterologous tissue in, 173–174
 inflammatory diseases of, 158–166
 intraepithelial neoplasia of, *see* Cervical intraepithelial neoplasia (CIN)
 malignant neoplasms of, 246–249
see also Cervical carcinoma
 metastatic tumors to, 247, 249
 normal morphology and physiology of, 142–155
 in pregnancy and puerperium, 155–156
 pseudotumors of, 166–170
 radiation effects on, 248–251
 squamocolumnar junction of, 147–151
 staining tests of, 203
 transformation zone of, 147–155
 uterine, tumors of, in animals, 913–916
- Chancres, 44
- Chancroid, 47
- Charcot-Böttcher filaments, 636–637
- Chemical carcinogens, *see* Carcinogens, chemical, in animals
- Chiari-Frommel syndrome, 897
- Chlamydia* infection
 in cervix, 162–163
 cytology of, 883
 in endometrium, 296
 in ovary, 473
- Chloroma, 737
- Chondroma, ovarian, 729–730
- Chondrosarcoma, ovarian, 730–731
- Chorangioma, 823–825
- Chorangiosis, 806
- Chorioamnionitis, 784–789
- Choriocarcinoma
 arising in placenta, 862
 atypical, 862
 behavior, 861–862
 of cervix, 246–247
 clinical features of, 858–860
 defined, 836
 of endometrium, 354–356
 liver metastases from, 860
 metastatic, 860
 nongestational, 684–686
 pathologic features of, 860–861
 spontaneous, in animals, 908
 teratomatous, 684
 uterine, 860–861
- Chorioepithelioma, atypical, 862
- Chorioepitheliosis, 862
- Chorion frondosum, 771
- Chorion laeve, 771, 773
- Chorioepithelioma, 684
- Chorionic gonadotropin, *see* Human chorionic gonadotropin (hCG)
- Chromosomes, sex, *see* Sex chromosomes
- Ciliated carcinoma, 347–348
- Ciliated cell metaplasia
 in endometrium, 328–329
 in endometriosis, 523
- CIN, *see* Cervical intraepithelial neoplasia
- Circummarginate placenta, 777
- Circumvallate placenta, 777
- CIS, *see* Carcinoma in situ
- Clear cell adenofibroma, 587
- Clear cell carcinoma, 121–127, 240, 353–354, 534–535, 587–592
 of low malignant potential (LMP), of ovary, 587
- Clear cell cystadenofibroma, 587
- Clear cell hidradenoma, 64
- Clear cell leiomyoma, 377–379
- Clear cell metaplasia, 329, 330
- Clear cell tumor, of ovary, 586–589
 benign, 587
 malignant, 587–589
- Clitoris, 36, 37–39
- Cloaca, 3
- Cloacal plate, 2
- Clomiphene citrate (Clomid), 313–314
- Clue cells, 105, 882, 883
- CMV, *see* Cytomegalovirus infection
- Coccidioidomycosis
 of endometrium, 297
 of ovary, 477
- Coelomic cavity, 2
- Colonic endometriosis, 528
- Colposcopy, 202–209
- Columnar epithelium, cervical, 145–147
- Condyloma
 atypical, 191
 cervical, *see* Cervical condyloma
 vaginal, 106
 vulvar (condylomata acuminata), 39–42
 condylomata lata, 44–45
 giant, of Buschke-Lowenstein, 41
- Contraceptives, oral (OCP), 183, 236, 311–313, 892
 in animals, 911
- Cornual pregnancy, 422
- Corpus albicans, 457, 458, 465
- Corpus atreticum, 458
- Corpus fibrosum, 458–459
- Corpus luteum, 438, 451–455
 of pregnancy, 455–457
- Corpus luteum cysts, 481–483
- Cortical granulomas, 478, 479
- Crohn's disease, 49, 419
- Crowded cell index, 895
- Cryosurgery, 208, 891
- Cryptococcosis, 297
- Cumulus oophorus, 447
- Curettings
 cytogenetic studies of, 940
 endocervical, 202–205, 207–208, 335, 927
 endometrial, 315–316, 335, 928
- Cushing's syndrome, 648
- Cutaneous endometriosis, 532
- Cutaneous endosalpingiosis, 536, 539
- Cylindroma, 243
- Cystadenocarcinoma
 extraovarian serous, 539
 retroperitoneal mucinous, 539–540
 serous, 571–572
- Cystadenofibroma
 clear cell, 587
 endometrioid, 578
 mucinous, 574
 serous, *see* Serous cystadenofibroma
- Cystadenoma
 in animals, 902
 microscopic features of, 567
 mucinous, 573–547
 serous, 561–562
- Cystic atrophy of endometrium, 286
- Cystic follicles, 438
- Cystic hyperplasia of endometrium, 323
- Cystic lymphangioma, 547
- Cystic mesothelioma, benign, 546–547
- Cystic teratoma, *see* Mature cystic teratoma
- Cysts, ovarian, nonneoplastic
 of follicular origin
 large solitary luteinized, 483

- multiple, 483-485
 solitary, 481-483
 inclusion surface epithelial, 478
 Cytokeratin, 441, 598-599, 638
 Cytology, 876-898
 Cytomegalovirus (CMV) infection
 of endometrium, 297-298
 of ovary, 476-477
 of placenta, 790-792
 Cytomorphology, quantitative, 332-333
 Cytotoxic drugs, cytologic changes secondary to, 503-504
 in cervix, 891
 in ovary, 503-504
 Cytotrophoblast, 684-685, 769-772, 839-845
- Danazol, and endometriosis, 524, 529
 Darier's disease, 50-51
 Decidual polyp, true, 167-168
 Decidual reaction, 283-284, 771
 ectopic, 442, 541-542, 544, 545
 ovarian, 498-499
 Dehydroepiandrosterone (DHEA), 21
 Dermatofibroma, 62
 Dermatofibrosarcoma protuberans, 81
 Dermoid cyst, 690-693
 DES, *see* Diethylstilbestrol *entries*
 DESAD (diethylstilbestrol adenosis) project, 183
 Desmoid tumors, 62
 20, 22-Desmolase deficiency, 23
 Desmosome-tonofilament complexes, 232
 DHEA (dehydroepiandrosterone), 21
 DHT (dihydrotestosterone), 16, 19
 Diabetes mellitus
 ovary in, 503
 placenta in, 806-807
 Diamniotic-dichorionic twin placenta, 779, 781-782
 Diamniotic-monochorionic twin placenta, 779, 781
 DIC (disseminated intravascular coagulation), 650
 Dichorionic placenta, processing of, 939
 Diethylstilbestrol (DES), 13, 97, 413, 891
 changes related to in utero exposure to, 121-137
 cervical intraepithelial neoplasia and, 135, 183
 to produce tumors in animals, 904-905, 910-911
 Diethylstilbestrol adenosis (DESAD) project, 183
 Digynic conceptus, 838
 Dihydrotestosterone (DHT), 16, 19
 Dysgerminoma, *see* Dysgerminoma
- Disseminated histiocytosis, 826, 827
 Disseminated intravascular coagulation (DIC), 650
 Disseminated peritoneal leiomyomatosis, 383-384, 542
 Divergent infarcts, 800
 Dizygotic triplets, 784
 Dizygotic twins, 779
 DNA (Fuclgen) microspectrophotometry, 198, 200, 333
 Döderlein bacilli, 880, 882
 Donovan bodies, 46
 Dysgenetic gonad, tumor of, 704
 Dysgerminoma, 32
 in animals, 902
 gonadoblastoma with, 705, 707
 with syncytiotrophoblast cells, 643, 644
 Diskaryosis, 886
 Dysplasia, 177-178, 251, 884, 886-888
- EBV, *see* Epstein-Barr virus infection
 ECC, *see* Endocervical curettage
 Echinococcosis, ovary, 476
 Eclampsia, 804-806
 Ectoderm, 1-2
 Ectopic human chorionic gonadotropin (hCG) production, 648-649
 Ectopic decidual reaction, 498-499, 541-542, 544-545
 Ectopic gestational trophoblastic disease, 866-868
 Ectopic hilus cells, 460
 Ectopic pregnancy, 421-423
 tubal, salpingectomy for processing of, 935-936
 Eczema, 56
 Edema
 massive ovarian, 491-495
 of umbilical cord, 816
 villous, 821, 823
 Edematous fibroma, 622
 EMA (epithelial membrane antigen), 198
 Embryo, 1-5
 early, extrauterine transplantation of, in animals, 908
 Embryoid bodies, 683
 malignant teratoma with, 682
 Embryoma, polyembryonic, 682
 Embryonal carcinoma, 661, 669, 670, 679-682
 Embryonal rhabdomyosarcoma, 114-116, 726-727
 Emphysematous vaginitis, 107
 Enchondromatosis, 616
 Endocervical adenocarcinoma, 13
 Endocervical curettage (ECC), 202-205, 207-208, 335, 927
 Endocervical ectropion, 151
- Endocervical glands, 145
 Endocervical hyperplasia
 atypical, 169-170
 microglandular, 156, 168-170
 Endocervical margin, 928-929
 Endocervical mucinogenesis, 148
 Endocervical polyps, 166-168
 Endocervicosis, 539
 Endocrine function, ovarian tumors with, 643-646
 Endoderm, 1-2
 Endodermal sinus tumor
 in ovary, 586, 669-679
 in vagina, 118, 120
 in vulva, 85
 Endodermal sinuses, 672
 Endolymphatic stromal myosis, 386, 389
 Endometrial adenocarcinoma, *see* Endometrial carcinoma
 Endometrial aspiration, 897
 Endometrial biopsy
 in infertility, 303-305
 tissue processing of, 928
 Endometrial breakdown, estrogen withdrawal, 300-301
 Endometrial carcinoma, 338-367, 745
 adenomyosis and, 363
 adenosquamous, 350-351
 ciliated, 347-348
 clear cell, 353-354
 clinical and pathologic features of, 339-359
 clinical risk factors for, 359-361
 cytologic detection of, 892-893
 endometrial hyperplasia as precursor of, 334-335
 estrogen receptors and, 360-361
 etiology of, 338-339
 glassy cell, 356
 gross appearance of, 339-340
 histologic effects of treatment of, 365-367
 histopathologic classification of, 343-357
 immunocytochemistry and, 358-359
 lymph node metastasis from, 346
 metastasis, *see also* specific sites from, 345
 to, 356-357
 microscopic appearance and clinicopathologic correlation of, 340-357
 mixed types of, 356
 mucinous, 351-352
 nonspecific, 356
 papillary, 345, 346, 347
 pathogenetic forms of, 339
 pathologic risk factors for, 361-364
 progesterone receptors and, 360-361
 progestins and, 366-367

- Endometrial carcinoma (*cont.*)
 quantitative microscopy and, 358
 radiation and, 365-366
 residual, in uterus, 335-336
 secretory, 346-347
 serous, 345, 352-353
 squamous, 354
 treatment of, 364-365
 typical, 343-348
 ultrastructure of, 357-358
 undifferentiated, 354-356
 well-differentiated, 335, 340-344
- Endometrial colonization, 529-530
- Endometrial cycle, 260-261
- Endometrial hyperplasia, 322-336
 adenomatous, 323
 adjunctive techniques in
 characterization of, 332-334
 with atypia, 325-327
 without atypia, 324-325, 332
 atypical, 323, 325-327
 behavior of, 334
 classification of, 323-324
 complex, 325
 complex atypical, 325-326
 cystic, 323
 defined, 334
 microscopic appearance, 324-332
 as precursor of endometrial
 carcinoma, 334-335
 simple, 324-325
 simple atypical, 325-326
 stromal, 331-332
 subdivision of, 334
 treatment of, 335-336
- Endometrial metaplasia, 326-331
 ciliated cell, 328-329
 clear cell, 329-330
 eosinophilic, 329
 hobnail, 329-330
 mucinous, 329
 papillary, 329-330
 squamous, 326-328
 tubal, 328-329
- Endometrial polyps, 305-307
- Endometrial stroma, 283, 285
- Endometrial stromal invasion, 340-343
- Endometrial stromal nodules, 387-388
- Endometrial stromal sarcoma, 388-392
- Endometrial stromal tumors, 386-393
- Endometrial stromal variants, 392-393
- Endometrial vascular alterations
 during menstrual cycle, 259
- Endometrioid adenofibroma, 578
- Endometrioid carcinoma
 of ovary, 534-536, 579-583
 of uterus, 343-348
- Endometrioid cystadenofibroma, 578
- Endometrioid lesions, peritoneal, 540
- Endometrioid stromal sarcoma, 534-535
- Endometrioid tumors, of ovary, 578-584
 in endometriosis, 534
 of peritoneal origin, 540
- Endometrioid-type adenocarcinoma, 238
- Endometrioma, 519
 vulvar, 63
- Endometriosis, 516-536
 abdominal, 533
 of bladder, 530-532
 of breast, 533
 cervical, 172, 529
 clinical aspects of, 526-527
 colonic, 528
 complications of, 526
 of cul-de-sac, 520-521
 cutaneous, 532
 definition of, 516
 differential diagnosis of, 524
 etiologic factors in, 518-519
 hyperplasia within, 524
 immunoglobulins and, 527
 infertility in, 527-528
 inguinal, 533
 intestinal, 528-529
 intraoperative implantation of, 518
 lower genital tract, 529
 of lymph nodes, 532
 lymphatic spread of, 518
 menstrual implantation of, 517-518
 metaplasia in, 523
 metaplastic theory of, 518
 metastatic theory of, 517-518
 musculoskeletal, 533
 neoplasms arising from, 533-536
 ovarian, 519-528
 pathogenesis of, 517-519
 pelvic peritoneal, 519-528
 pleuropulmonary, 533
 postsalpingectomy, 530, 531
 pregnancy and, 526
 prostaglandins and, 527
 of rectosigmoid, 528
 renal, 531
 scar-related, 532
 subarachnoid, 533
 tubal, 529-530
 ultrastructure of, 525
 ureteric, 531
 urethral, 531
 urinary tract, 530-532
 vaginal, 529
 vascular spread of, 518
 vulvar, 63, 532
- Endometriosis-related infertility, 527-528
- Endometriotic cysts, 519
 rupture of, 526-527
- Endometriotic stroma, 523
- Endometritis, 293-299
 acute, 294-295
 chronic
 nonspecific, 295-296
 specific types, 296-299
 pneumopolycystic, 298
 tuberculous, 296-297
- Endometrium
 benign diseases of, 292-316
 benign tumors of, 305-309
 bone in, 310
 cartilage in, 310
 choriocarcinoma of, 354-356
 contraceptives, oral, effects on, 311-314
 cystic atrophy, 286
 cystic hyperplasia, 323
 dating of, 264-272
 developmental anatomy of, 257-258
 estradiol and, 260
 estrogens and, 311
 functional disorders of, 299-303
 gestational, 279-286
 heterologous tissue in, 309-310
 inactive and atrophic, 285-288
 inflammation of, *see* Endometritis
 IUDs and, 314-315
 menstrual phase of, 272-279
 metastasis to ovary from, 356
 normal, morphology and physiology
 of, 262-279
 proliferative, 262-267
 prostaglandins and, 314
 secretory phase of, 264-272
 smooth muscle in, 310
 steroid hormone and receptor interactions in, 260-262
 steroid hormones, effects on, 311-314
 tumors metastatic to, 356-357
 vascular anatomy of, 258-260
- Endomyometriosis, 473, 523
- Endoplasmic reticulum (ER), 444-446
 rough (RER), 431, 841-846
 smooth (SER), 453-454
- Endosalpingiosis, 524, 536-539, 601
 atypical, 537
 histogenesis of, 538-539
- Endosalpingiotic glands within pelvic lymph nodes, 542-544
- Endothelioma, 669
- Endovasculitis, hemorrhagic, 795, 796, 797
- Enterobius vermicularis*, 49, 476, 524
- Enzymatically active stromal cells, 442, 597
- Eosinophilic index, 895
- Eosinophilic metaplasia, 329
- Epidermidization of cervical mucosa, 152, 173
- Epidermodysplasia verruciformis, 180

- Epidermoid cysts, 483, 703
 Epithelial carcinoma, mixed, 243-245
 Epithelial inclusion cysts
 of cervix, 170
 of ovary, 465, 478
 Epithelial membrane antigen (EMA), 198
 Epithelial tumors
 of ovary, 13, 560-601
 classification of, 560-561
 clinicopathologic features of, 561-597
 extraovarian peritoneal papillary and glandular lesions not associated with, 601
 histologic classification of, 561
 immunocytochemistry of, 597-601
 luteinized and enzymatically active stromal cells in, 597
 metastasis from, *see* specific sites
 metastasis to, 356, 747
 modification of WHO histologic classification of, 562
 staging of, 563
 Epithelioid leiomyoma, 377-379
 Epithelioid leiomyosarcoma, 385
 Epithelioid sarcoma, 81
 Epithelioma Pflügerien, 709
 Epstein-Barr virus (EBV) infection, 44
 Equine ovarian tumors, 901
 Erythrasma, 48
 Essential hypertension, placenta in, 806
 Estradiol, endometrium and, 260
 Estrogen receptors, 260-261
 endometrial carcinoma and, 360-361
 endometriosis and, 525
 Estrogen withdrawal bleeding, 299-302
 Estrogen withdrawal endometrial breakdown, 300-301
 Estrogens
 in animals, 904-905, 910-911, 913-914
 endometrium and, 260-262, 311
 replacement therapy for, 338-339
 Exaggerated placental site, 283, 836
 Exenteration, pelvic, 931
 Extrachorial placenta, 776-777
 Extraovarian Brenner tumor, 541
 Extraovarian peritoneal papillary and glandular lesions, 601
 Extraovarian serous neoplasia, 539
 Extruterine transplantation of early embryos in animals, 908
 Extravillous trophoblast, 839
 Fallopian tube, *see also* Tubal entries
 anatomy of, 409-410
 benign neoplasms of, 424-426
 carcinoma of, 744-745
 congenital anomalies of, 413
 diseases of, 409-432
 endometriosis of, 529
 function of, 409
 histology of, 410-412
 intussusception of, 414
 large operative specimens, tissue processing of, 935-936
 malignant neoplasms of, 426-430
 metastatic tumors of, 429-430
 nerve supply of, 410
 paratubal tumors and cysts, 430-432
 physiology of, with morphologic correlation, 412-413
 prolapse of, 106, 413-414
 salpingectomy, tissue processing of, 935-936
 salpingitis and, 414-421
 torsion of, 413
 Fasciitis
 necrotizing, 49
 nodular, 62
 Feline ovarian tumors, 901
 Female pseudohermaphroditism, 20-22
 Feminization, testicular, 12-13, 24-25
 Fenestrate placenta, 776
 Ferning reaction, 146
 Fetal artery thrombosis, 803
 Fetal death in utero, 817
 Fetal disorders, placenta in, 803-809
 Fetal hydrops, nonimmune, 821
 Fetal leukocytes, 785-786
 Fetal lung, in chorioamnionitis, 788
 Fetal origin, tumors of, in animals, 907-908
 Fetectomy in animals, 908
 Fetomaternal hemorrhage, 802
 Fetus
 acardiac, 783
 monosomy X, 820-821
 triploidy, 818-820
 trisomy 13, 818
 Fetus papyraceus, 783, 784
 Fibrin, subchorionic, 799
 Fibrin deposition, perivillous, 798-799
 Fibroadenoma, 171
 Fibroepithelial polyps, 63, 108
 Fibrohyaline nodules, 285, 286
 Fibroma
 in ovary, 621-623, 723
 in vagina, 108-109
 in vulva, 62
 Fibromatosis, ovarian, 492-495
 Fibromatous nodules, 621
 Fibrosarcoma, ovarian, 622, 723-724
 Fimbria ovarica, 412
 Fimbriae, 409
 Fixatives, 926-927
 Fluorescent treponemal antibody-absorbed (FTA-ABS) test, 45
 Foam cells, 331-332
 Focal inflammation, subacute, of endometrium, 296
 Folded index, 895
 Folic acid deficiency, 881
 Follicle cysts, 481-483
 multiple, 483-485
 solitary
 differential diagnosis of, 483
 large luteinized, 483
 Follicle-stimulating hormone, 302, 311, 451, 455, 459, 466, 487-488
 Follicles
 antral, 446, 447
 atretic, 457-459
 cystic, 438
 graafian, 447
 maturing, 446-451
 preantral, 446, 447
 primordial, 444-446
 Follicular hyperthecosis, 486
 Follicular theca interna cells, 442
 Folliculogenesis, 446-448
 Folliculome lipidique, 625
 Foreign body granuloma
 of endometrium, 298
 of fallopian tube, 417-420
 of ovary, 477-479
 of vulva, 48
 Formalin fixation, 926
 Fowl ovarian tumors, 901
 Fox-Fordyce disease, 50
 Fractional curettage, 335, 360
 Fraternal twins, 779
 Freckles, 52-53
 FSH, *see* Follicle-stimulating hormone
 FSH-suppressing substance, 451
 FTA-ABS (fluorescent treponemal antibody-absorbed) test, 45
 Functional polyps, 306-307
 Fungal cervicitis, 165
 Fungal infections of ovary, 477
 Funisitis, subacute necrotizing, 787
 G-6-PD (glucose-6-phosphate dehydrogenase), 186
 Galactosemia, 501
 Gallbladder, tumors, metastatic to ovary, 758-759
 Ganglioneuroma, ovarian, 731
 Gardnerella vaginalis, 104-105
 Gastric carcinoma, metastatic to ovary, 748-752
 Genital tract neoplastic syndrome, lower, 112-113
 Genital tubercle, 11
 Genital vaccinia, 884
 Genitalia
 external, development of, 12
 female, anatomy of, 36-39

- Germ cell-sex cord-stromal tumors, mixed, 709-713
- Germ cell tumors
- AFP and, 678-679, 680
 - extragonadal, 12, 118
 - of ovary, 659-713
 - carcinoid tumors, 696-701
 - choriocarcinoma, 684-686
 - classification of, 660
 - clinical and pathologic features of, 661
 - containing syncytiotrophoblastic cells, 644, 655, 682
 - dysgerminoma, 660, 661-669
 - embryonal carcinoma, 679-682
 - endodermal sinus tumor, 669-679
 - gonadoblastoma, 704-709
 - histogenesis of, 660
 - immature teratoma, 686-688
 - mature cystic teratoma, 690-694
 - mature solid teratoma, 688-690
 - mixed germ cell-sex cord-stromal tumors, 709-713
 - mixed germ cell tumors, 690, 703, 709
 - polyembryoma, 682-684
 - struma ovarii, 694-696
 - strumal carcinoid, 701-703
 - teratoma, 686
- Germ cells, 5
- Germinoma, *see* Dysgerminoma
- Gestation, twin, 779-784
- Gestational endometrium, 279-286
- Gestational hyperplasia, 279-283
- Gestational trophoblastic disease (GTD), 484, 835-869
- blood groups and, 838
 - classification of, 836
 - clinicopathologic features and behavior of, 846-868
 - cytogenetics of, 838-839
 - defined, 836
 - at ectopic sites, 430, 866-868
 - epidemiology and risk factors of, 836-839
 - immunocytochemistry of, 845-846
 - incidence and geographic distribution of, 837
 - management of, 868-869
 - morphology and immunocytochemistry of trophoblast in, 839-846
 - previous obstetric history and, 837-838
 - treatment of, 868-869
- Giant cell reaction, foreign body, *see* Foreign body granuloma
- Giant cell tumor of ovary, 731
- Glassy cell carcinoma, 244-245, 356
- Glia tissue in endometrium, 310
- Glioma
- of cervix, 173
 - of uterus, 310
- Gliomatosis, peritoneal, 524
- Glucocorticoids, biosynthesis of, 20
- Glucose-6-phosphate dehydrogenase (G-6-PD), 186
- Glutaraldehyde, 926-927
- Goblet cell carcinoid, 700-701
- Gonadal dysgenesis
- asymmetric, 28
 - cervical smear in, 896
 - mixed, 28-32
 - pure, 28
- Gonadoblastoma, 31-32, 704-709
- with dysgerminoma, 705, 707
- Gonadotropins, to produce tumors in animals, 905
- Gonocytoma, 661, 704, 709
- Gonorrhoea, 104
- Gorlin's syndrome, 621
- Graafian follicles, 447
- Granular cell tumors, 60, 110-111
- Granulocytes, stromal, 294
- Granulocytic leukemia, involving ovary, 737-738
- Granulocytic sarcoma, involving ovary, 737
- Granuloma inguinale, 46, 47
- Granulomas, *see* Foreign body granuloma
- Granulomatosis, Langerhan's, 83
- Granulomatous foreign body infection, of endometrium, 298
- Granulomatous salpingitis, 417-420
- Granulosa cell tumors
- adult, 608-616
 - Sertoli-Leydig cell tumors versus, 634
 - carcinoid versus, 612
 - juvenile, 616-619
 - luteinized, 613
 - small cell carcinoma versus, 617
 - undifferentiated carcinoma versus, 599, 612
- Granulosa cells, 444-455
- Granulosa-stromal cell tumors, 608-624
- Granulosa-theca cell tumor, 613
- Grimelius staining
- of cervical carcinoma, 245, 247
 - of endometrial carcinoma, 359
- GTD, *see* Gestational trophoblastic disease
- Gynandroblastoma, 608, 634-635
- Gynecologic and obstetric specimens
- biopsies, 927-928
 - cellular samples, 897
 - cervical cone biopsy, 927-929
 - curettings, 927-928
 - cystectomy, ovarian, 936-937
 - drawings, 926
 - fixatives, 926-927
 - gross description, processing, and reporting of, 925-940
 - hysterectomy, 931-935
 - oophorectomy, 936
 - pelvic exenteration, 931
 - placental examination, 937-940
 - salpingectomy, 935-936
 - section codes, 926
 - vaginectomy, 931
 - vulvectomy, 928-931
- Haemophilus ducreyi*, 47
- Hailey-Hailey disease, 51-52
- HAIR-AN syndrome, 487, 491-492
- Hamster cheek pouch, choriocarcinoma in, 916
- hCG, *see* Human chorionic gonadotropin
- Hemagioendothelial sarcoma (hemangioendothelioma) of ovary, 728-729
- Hemangioma
- of cervix, 170
 - of ovary, 727-728
 - of placenta, 823-825
 - of umbilical cord, 824
 - of uterus, 402-403
 - of vulva, 59
- Hemangiopericytoma
- of ovary, 728-729
 - of uterus, 403
 - of vulva, 60
- Hemangiosarcoma, of ovary, 728
- Hematogenous infections of placenta, 789-790
- Hematologic disorders, ovarian tumors and, 649-650
- Hematoma
- marginal, 801-802
 - retroplacental, 800-801
 - subamniotic, 802-803
 - of umbilical cord, 816
- Hematopoietic tumors, involving ovary, 733-738
- Hematosalpinx, 421
- Hemorrhage, *see also* Bleeding
- fetomaternal, 802
 - Klime's, 802
 - ovarian, 502
 - retroperitoneal, 503
- Hepatocellular carcinoma, metastatic to ovary, 759
- Hepatoid pattern, of yolk sac tumor, 676
- Hernaphroditism, true, 32-33
- Hernia uteri inguinalis, 24
- Herpes genitalis, 163-164
- Herpes-like lesions, 164-165
- Herpes simplex virus infection
- cytologic features of, 883, 885
 - in relation to cervical neoplasia, 182
 - of placenta, 793
 - of vulva, 42, 44
 - in animals, 915

- Herpes vaginitis, 883, 885
 Herpes zoster, of vulva, 43
 Heterologous tissue in endometrium, 309-310
 5-HIAA (5-hydroxyindole acetic acid), and carcinoid syndrome, 697
 Hidradentitis suppurativa, 49-50
 Hidradenoma
 clear cell, 64
 papillary, 63-64
 High-grade stromal sarcoma of uterus, 388-392
 Hilar Leydig cell hyperplasia, 497-498
 Hilus cell tumors, 640, 641
 Hilus cells, embryology of, 6-7
 ectopic, 460
 ovarian, 459-463
 Hinselman test, 202, 206
 Histiocytes, cytology of, 878-879
 Histiocytoma, malignant fibrous, of vulva, 81
 Histiocytosis, disseminated, 826, 827
 Histoautoradiography, studies in endometrium, 333
 Hobnail cells
 in endometrium, 282
 in ovary, 588
 Hobnail metaplasia, 329, 330
 Hodgkin's disease localized to ovary, 735
 Hormonal cytology, 894
 Hormones, tumor induction in animals, 904-905, 910-911, 913-914
 hPL (human placental lactogen), *see* Human placental lactogen
 HPV, *see* Human papillomavirus infection
 HSV (herpes simplex virus) infection, *see* Herpes simplex virus infection
 Human chorionic gonadotropin (hCG), 16, 355, 457, 648-649, 665, 845, 847, 849, 868-869
 Human papillomavirus infection
 antigens of, 195-196
 of cervix, 177-182
 DNA of, 181-182
 molecular hybridization for typing, 200-201
 types of, 180
 of vagina, 106
 of vulva, 39-42
 Human placental lactogen (hPL), 773, 845, 847, 848, 849
 H-Y antigen, 15-16
 Hydatid disease, 419
 Hydatid of Morgagni, 431-432
 Hydatidiform mole
 classic, 849
 clinical features of, 853
 complete, 849-852
 defined, 836
 invasive, 857-858
 partial, 820, 821, 849-857
 pathologic features of, 855
 Hydrops, nonimmune fetal, 821
 Hydrosalpinx, 417
 5-Hydroxyindole acetic acid (5-HIAA), in carcinoid, 697
 17-Hydroxylase deficiency, 485
 21-Hydroxylase deficiency, 21
 17-Hydroxysteroid dehydrogenase deficiency, 23-24
 Hymen, 36
 imperforate, 39
 Hymenal tags and hymenal bands, 20
 Hyperandrogenism, 487, 491-492
 Hypercalcemia
 ovarian tumors and, 647
 small cell carcinoma of ovary and, 647-648
 Hyperkeratosis, cervical, 159, 161
 Hyperplasia(s), 307
 endocervical, *see* Endocervical hyperplasia
 endometrial, *see* Endometrial hyperplasia
 within endometriosis, 524
 Leydig cell, *see* Leydig cell hyperplasia
 mesothelial, 546
 stromal
 of endometrium, 331-332
 of ovary, 489-491
 Hyperplastic arteriosclerosis, in pregnancy, 806
 Hyperplastic polyps, 306
 Hyperplastic vulvar dystrophy, 56-57
 Hyperprolactinemia, 487
 Hyperreactio luteinalis, 483-485
 Hypertension, essential, placenta in, 806
 Hyperthecosis
 follicular, 486
 nodular, 639
 stromal, 489-491, 639
 Hypoglycemia, ovarian tumors and, 649
 Hypomenorrhea, 315
 Hypothalamic nucleus destruction, induction of tumors in animals during pregnancy, 909
 Hypothyroidism, juvenile, ovarian changes in, 485
 Hysterectomy
 in cervical adenocarcinoma, 241-242
 in cervical cancer, 233
 in cervical intraepithelial neoplasia, 203
 in cervical microinvasive squamous carcinoma, 223
 in endometrial carcinoma, 364-365
 in endometrial hyperplasia, 335-336
 in endometrial stromal sarcoma, 391-392
 in endometrioid carcinoma, 582
 in gestational trophoblastic disease, 869
 in invasive adenocarcinoma of fallopian tube, 428
 in ovarian carcinosarcoma, 585
 in ovarian clear cell carcinoma, 589
 in ovarian granulosa cell tumor, 614
 in ovarian immature teratoma, 688
 in ovarian insular carcinoid tumor, 698
 in ovarian malignant Brenner tumor, 596
 in ovarian malignant serous adenofibroma and cystadenofibroma, 573
 in ovarian mature cystic teratoma, 694
 in ovarian mesodermal mixed heterogeneous tumor, 586
 in ovarian mucinous carcinoma, 577, 701
 in ovarian serous carcinoma, 572
 of low malignant potential, 571
 in ovarian small cell carcinoma, 648
 in ovarian thecoma, 621
 in ovarian trabecular carcinoma, 699
 processing specimens from, *see* Gynecologic and obstetric specimens
 in uterine adenofibroma, 396
 in uterine adenomyoma, 402
 in uterine adenosarcoma, 397
 in uterine mixed müllerian tumor, 401
 Hysterosalpingography, in evaluation of infertility, 424
 Ichthyosis psoriasis uteri, 286, 354
 Identical twins, 779
 Illumination, constant bright, induction of tumors in animals, 904
 Immature teratoma, of ovary, 686-688
 Immune suppression, as a factor in cervical neoplasia, 184
 Immunocytochemistry (immunohistochemistry)
 of cervix, 162, 230-232
 of common epithelial tumors of ovary, 597-601
 of endometrial carcinoma, 358-359
 of endometrial hyperplasia, 333-334
 of gestational trophoblastic disease, 845-846
 of sex cord-stromal tumors, 638-639
 of trophoblast, 839-846
 Immunoglobulins, endometriosis and, 527

- Immunological suppression, induction
of tumors in animals, 916
- Inclusion cysts
of fallopian tubes, 424-425
of ovary, 478-480
of peritoneum, 546-548
- Infarct in placenta, 796-799
divergent, 800
- Infertility
endometrial biopsy in, 303-305
endometriosis-related, 527-528
endometrium in, 302
fallopian tube in, 423-424
intersex disorders and, 24-33
organic causes of, 304
ovary in, 487-488, 499-501
- Inguinal endometriosis, 533
- Inhibin-F, 451, 487
- Insular carcinoid, 696-698
- Insulin resistance, 487, 491-492
- Intercalary cells, 411
- Intermediate cells, 143
cytology of, 876-877, 880, 882
- Intermediate filaments, 598-599
- Intermediate trophoblast, 518, 770-773, 805, 839-843, 845-846
- International Federation of Gynecologists and Obstetricians (FIGO),
grading of endometrial cancer, 361
staging
of cervical cancer, 218-219
of endometrial cancer, 359
of ovarian cancer, 563
of vaginal cancer, 114
of vulvar cancer, 73
- Intersex disorders
classification of, 16
embryology of, 12-13
- Intervillous thrombus, 802-803
- Intestinal carcinoid, 697
- Intestinal carcinoma, metastatic, 752-754
- Intestinal endometriosis, 528-529
- Intestinal mucin antigens, 600
- Intraepithelial neoplasia
of cervix, *see* Cervical
intraepithelial neoplasia (CIN)
of vagina, *see* Vaginal
intraepithelial neoplasia (VAIN)
of vulva, *see* Vulvar intraepithelial
neoplasia (VIN)
- Intramesodermal cavities, in embryology,
2
- Intramural leiomyoma, 375
- Intramural pregnancy, 421
- Intranodal lesions, 542-545
- Intraoperative implantation of endometriosis, 518
- Intrauterine device (IUD)
cellular changes induced by, 884, 892
in animals, 913
ectopic pregnancy and, 422
endometrium and, 314-315
pelvic actinomycosis and, 474-475
- Intravascular trophoblastic migration,
804-805
- Intravenous leiomyomatosis, 381-382
- Invasive carcinoma, *see* specific sites
- Involucrin, 143, 230
- Iodine test, in cervix, 203, 206
- Irregular shedding, 302-303
- Islet carcinoid, 696-698
- Islet cell carcinoma, metastatic to
ovary, 759
- Isosexual precocity, granulosa cell tumors
of ovary and, 616
- IUD, *see* Intrauterine device
- Juvenile hypothyroidism, ovarian
changes associated with, 485
- K cells, 453-456
- Kaposi's sarcoma, 81-82
- Kartagener's syndrome, 413
- Karyolysis, 880, 881
- Karyopyknotic index, 895
- Karyorrhesis, 880, 881
- Karyotypes, abnormal, in spontaneous
abortion, 820
- Karyotyping, 818
- Keratin formation, 228-229
- Keratinization, surface, 192, 197
- Keratinous cysts of vulva, 58
- Keratoacanthoma, 65-66
- Keratohyaline granules, 357, 877
- Keratoses, seborrheic, 66
- Keratoses follicularis, 50-51
- 17-Ketosteroids, 626, 640-641
- Kevorkian biopsy punch, 204, 207
- Kline's hemorrhage, 802
- Klinefelter's syndrome, 26
- Knots in umbilical cord, 815-816
- Koilocytosis, 40, 41, 178, 188-191, 883
- Krukenberg tumors, 632, 644, 748-752
- Labia majora, 36
- Labia minora, 36
hypertrophy and asymmetry of, 39
- Labioscrotal fold, 11-12
- Lactic dehydrogenase (LDH), as tumor
marker for dysgerminoma, 667
- Laminated intervillous thrombus, 802
- Langerhan's granulomatosis, 83
- Langhans' giant cells, in tuberculous
endometritis, 297
- LDH (lactic dehydrogenase), 667
- Leiomyoblastoma, 377-379
- Leiomyoma
of cervix, 170, 171
of fallopian tube, 425
of ovary, 724-725
of uterus, 374-384
atypical, 377
benign metastasizing, 382-383
cellular, 376
clear cell, 377-379
epithelioid, 377-379
with increased mitotic figures, 385
intramural, 375
leiomyosarcoma versus, 384
myxoid, 380
plexiform, 377-379
related entities and other types of,
380-384
specific subtypes of, 376-379
submucosal, 375
subserosal, 375
symplastic, 377
with tubules, 380
vascular, 380
of vagina, 108
of vulva, 60
- Leiomyomatosis, 544-545
diffuse, 380-381
disseminated peritoneal, 383-384,
524, 542
intravenous, 381-382
of lymph nodes, 544-545
- Leiomyosarcoma
of ovary, 725
of uterus, 384-385
epithelioid, 385
leiomyoma versus, 384
myxoid, 385
of vagina, 114-115
of vulva, 81
- Lentigo simplex, 53
- Leprosy, ovary, 476
- Leukemia, involvement of ovary by,
737-738
- Leukocyte common antigen (LCA),
735
- Leukoderma, 52
- Leukoplakia, 159
- Leydig cell agenesis, 23
- Leydig cell hyperplasia, 497-498
- Leydig cell tumors, 619, 620, 639-641
- Leydig cells, 4, 6, 16, 442-443, 498
- LH, *see* Luteinizing hormone *entries*
- LHRF, *see* Luteinizing hormone-releasing
factor
- Lice, involvement of vulva, 48
- Lichen sclerosus, 55-56
- Lipid (lipoid) cell tumors, 639
- Lipid-rich Sertoli cell tumors, 625
- Lipoleiomyoma, 380
- Lipoma, of vulva, 63
- Listeria monocytogenes*, 793-795
- LMP (low malignant potential), tumors
of ovary, defined, 569
- Lobulated ovary, 472
- Lobules, of placenta, 773

- Low-grade stromal sarcoma (LGSS), 388-391
- LPD, *see* Luteal phase defect
- Luteal phase defect (LPD), 302
- Luteinized cells, in common epithelial tumors, 597
- Luteinized follicle cysts, large solitary, 483
- Luteinized granulosa cell tumor, 613
- Luteinized stromal cells, 442, 489, 643
- Luteinized thecoma, 619, 620
- Luteinized unruptured follicle syndrome, 519, 527
- Luteinizing hormone (LH), 302, 451, 455, 466, 488
- Luteinizing hormone releasing factor (LHRF), 487-488
- Luteoma
 pregnancy, 495-497, 642
 stromal, 639, 640
- Lymph nodes
 ectopic tissue within, 542-544
 endometriosis of, 532
- Lymphangioma
 cystic, of peritoneum, 547
 ovarian, 729
- Lymphangiosarcoma, ovarian, 728-729
- Lymphatics
 of cervix, 141
 of ovary, 439-440
 of uterus, 260
 of vagina, 101-103
 of vulva, 39, 931
- Lymphocytic leukemia, involvement of ovary, 737-738
- Lymphogranuloma venereum, 46-47
- Lymphoid hamartoma, 63
- Lymphoma
 Burkitt's, involvement of ovary, 736-737
 of fallopian tube, 430
 of ovary, 734-737
 of uterus, 404
- Malakoplakia, 298-299, 475-476
- Male pseudohermaphroditism, 22-26
- Marginal hematoma, 801-802
- Marginal insertion of umbilical cord, 813
- Masculinization, 21, 626
- Maternal disorders, placenta in, 803-809
- Maternal IgG antibody, association with recurrent abortions, 818
- Maternofetal rhesus incompatibility, 807-809
- Maturation index, 895
- Maturation value, 895
- Mature cystic teratoma, 690-693
 with malignant transformation, 693-694
- Mature solid teratoma, 688-690
- Maturing follicles, 446-451
- McCune-Albright syndrome, 483
- Meconium stain, 812
- Mediastinal tumors, metastatic to ovary, 761
- Meigs-like syndrome, 527
- Meigs' syndrome, 494, 621
- Melanoma
 of cervix, 246, 249
 metastatic to ovary, 760-761
 metastatic to placenta, 825
 of vagina, 118-121
 of vulva, 83-85
- Melanotic tumor of ovary, 703
- Membranous chorioamnionitis, 785
- Menopause
 ovary in, 464-466, 500-501
 vaginal smear in, 896
- Menstrual cycle, *see* Endometrium
- Menstrual implantation of endometriosis, 517-518
- Menstruation, corpus luteum of, 451-455
- Mesenchymal conditions, miscellaneous, of uterus, 401-404
- Mesenchymal lesions, subperitoneal, 541-542
- Mesenchymal (mesodermal) tumors
 of cervix, 170, 399
 of fallopian tube, 425-426, 429
 of ovary, 722-733
 of uterus, 13, 373-404
 endometrial stromal tumors, 386-393
 mixed mesodermal tumors, 393-401
 smooth muscle tumors, 374-386
 of vagina, 108-111, 114, 118
 of vulva, 59-63, 81-82
- Mesenchymoma, 607
- Mesoblastoma, 669
- Mesoderm, 1-2
- Mesodermal mixed tumors (MMT)
 of fallopian tube, 429
 of ovary, 582-586
 of peritoneum, 540
 of uterus, 393-401
 of vagina, 116-117
- Mesonephric carcinoma, 243
- Mesonephric cysts, 59
- Mesonephric duct, *see* Wolffian duct
- Mesonephric (duct) remnants, 172-173, 412, 463
- Mesonephric hyperplasia, florid, 173
- Mesonephric papilloma of children, 171-172
- Mesonephroma, 586, 589, 669
- Mesosalpinx, 410
- Mesothelial hyperplasia, 480, 546
- Mesothelial proliferations, 480, 545-548
- Mesothelioma
 adenomatoid, 402
 benign, 425-426
 benign cystic, 546-547
 diffuse malignant, 548
 peritoneal, 601, 732-733
 well-differentiated papillary, 548
- Mesovarium, 438
- Metaplasia(s)
 cervix, squamous, 151-155
 defined, 881
 endometrial, *see* Endometrial metaplasia
 in endometriosis, 523
 ovarian stromal, 498-499
 vagina, in utero DES and, 135
- Metaplastic cells, cytology of, 881-883
- Metaplastic theory of endometriosis, 518
- Metastatic theory of endometriosis, 517-518
- Metastatic tumors, *see also* specific sites
 to cervix, 247, 249
 to endometrium, 356-357
 to ovary, 742-762
 to placenta, 825-827
 to vagina, 119
 to vulva, 85-86
- Methotrexate, 686
- Michaelis-Gutman bodies, 298
- Microcystic pattern, of endodermal sinus tumor, 671
- Microglandular (endocervical) hyperplasia, 135-136, 156, 168-170
- Microinvasive carcinoma, of cervix, 218-224
- Microspectrophotometry, DNA, in cervical intraepithelial neoplasia, 198, 200
 endometrial hyperplasia, 333
- Mineralocorticoids, biosynthesis of, 20
- Minimal deviation adenocarcinoma, 242
- Mites, 48
- Mitochondria, 450
- Mitotic figure(s)
 abnormal (AMF), 193-194, 200-201
 counts in diagnosis of ovarian steroid cell tumors, 642
 uterine adenosarcoma, 396
 uterine leiomyosarcoma, 384-386
 uterine stromal nodule, 387
 uterine stromal sarcoma, 390
- Mixed gonadal dysgenesis, 23-32

- Mixed mesodermal tumor (MMT), *see* Mesodermal mixed tumors
- MMT (mixed mesodermal tumor or mixed müllerian tumor), *see* Mesodermal mixed tumors
- Mole, *see* Hydatidiform mole
- Molluscum contagiosum, 45-46
- Monoamniotic-monochorionic twins, 779-784
- Monoclonal antibody TA-4, 230, 232, 234
- Monodermal teratoma, 703
- Monosomy X, 820, 822
- Monozygotic triplets, 784
- Monozygotic twins, 779
- Monro's abscesses, 52
- Mons pubis, 36
- Morgagni, hydatid of, 431-432
- Mortality, perinatal, 781-782
- Morula, 1
- Mouse sarcoma virus (MSV), induction of tumors in animals, 908
- Mucinogenesis, endocervical, 148
- Mucinous adenofibroma, 574
malignant, 578
- Mucinous carcinoid, 700-701
- Mucinous carcinoma, 351-352, 575-577
of low malignant potential (LMP), 574-578
of peritoneal origin, 539
- Mucinous columnar cells, 130, 133
- Mucinous cystadenofibroma, 574
malignant, 578
- Mucinous cystadenoma, 573-574
- Mucinous intestinal (colloid) adenocarcinoma, of cervix, 238, 240
- Mucinous lesions, peritoneal, 539-540
- Mucinous metaplasia, of endometrium, 329
- Mucinous tumors, of ovary, 573-578, 645
- Mucoepidermoid carcinoma, of cervix, 245
- Mucous cysts of vulva, 58
- Müllerian duct syndrome, persistent, 24
- Müllerian ducts, 7-11, 17-19
atresia of, 293-294
fusion defects of, 293, 473
- Müllerian-inhibiting substance (MIS), 12-13, 16
- Müllerian mixed tumors (MMT), *see* Mesodermal mixed tumors
- Müllerian system, secondary, 516, 518
lesions of, 536-545
- Müllerian type, benign glands of, involving lymph nodes, 542-544
- Multilobate placenta, 776
- Multinucleated histiocytes, cytology, 879
- Multiple pregnancy, 779-784
- Mumps oophoritis, 477
- Musculoskeletal endometriosis, 533
- Mycoplasma* infection, of endometrium, 296
- Myleran (busulfan), cellular changes secondary to, 891
- Myolipoma, 380
- Myometrial hypertrophy, 380-381
- Myometrial invasion, endometrial carcinoma, 340, 362-363
- Myometrium, developmental anatomy of, 257-258
- Myxoid leiomyoma, 380
- Myxoid leiomyosarcoma, 385
- Myxoma, ovarian, 724
- Nabothian cysts, 147
- Native portio epithelium, 142-144
- Navicular cells, 877, 896
- Necrotizing fasciitis, 49
- Necrotizing funisitis, subacute, 787
- Necrotizing villitis, 790
- Neoplastic syndrome, lower genital tract, 112-113
- Nervous system disorders, ovarian tumors and, 649
- Neurilemmoma, ovarian, 731
- Neuroblastoma, placental metastases from, 827
- Neurodermatitis, 56
- Neuroendocrine carcinoma, of cervix, 245-247
- Neurofibroma
of ovary, 731
of vulva, 60-61
- Neurofibrosarcoma, ovarian, 731
- Nevomelanocytic nevi, 53-54
- Nexuses, 232
- Nodular fasciitis, 62
- Nodular hyperthecosis, 639
- Nonimmune fetal hydrops, 821
- Nontrophoblastic tumors of placenta, 823-827
- Nuck, cysts of canal of, 59
- Obstetrical specimens, tissue processing, *see* Gynecologic and obstetrical specimens
- OC 125, 600
- Ollier's disease, 616
- Omphalomesenteric duct remnant, 812
- Oocyte deficiency in animals, 902
- Oocytes, 444
zona pellucida and, 448-449
- Oophorectomy, tissue processing, *see* Gynecologic and obstetrical specimens
- Oophoritis
actinomycotic, 475
animal, 903
autoimmune, 501-502
cytomegalovirus, 476-477
leprotic, 476
leutic, 476
mumps, 477
mycotic, 477
parasitic, 476
tuberculous, 475
xanthogranulomatous, 474
- Oophoroma folliculare, 589
- Optically clear nuclei, 282-283
- Oracon, 313
- Oral contraceptives, *see* Contraceptives, oral
- Organic polymer, 912-913
- Os aspiration, 202
- Osteoma, of ovary, 730
- Osteosarcoma, of ovary, 730-731
- Ovarian abscess, 474
- Ovarian amyloidosis, 503
- Ovarian artery, 438-439, 503
- Ovarian biopsy, tissue processing, 928
- Ovarian carcinoma, 13, 560-601
classification of, 560-561
clinicopathologic features of, 561-597
extraovarian peritoneal papillary and glandular lesions not associated with, 601
histologic classification of, 561
immunocytochemistry of, 597-601
luteinized and enzymatically active stromal cells in, 597
metastasis from, *see* specific sites
metastasis to, 356, 747
modification of WHO histologic classification of, 562
staging of, 563
- Ovarian chondroma, 729-730
- Ovarian chondrosarcoma, 730, 731
- Ovarian choriocarcinoma, 684-686
- Ovarian decidual reaction, 498-499
- Ovarian edema, massive, 491-495
- Ovarian endometriosis, 519-528
- Ovarian failure, premature, 499-502
- Ovarian fibroma, 723
- Ovarian fibromatosis, 491-495
- Ovarian fibrosarcoma, 723-724
- Ovarian fragmentation in animals, 911
- Ovarian ganglioneuroma, 731
- Ovarian grafting in animals, tumor induction, 904
- Ovarian granulocytic sarcoma, 737
- Ovarian granulomas, 477-478
- Ovarian hemangioma, 727-728
- Ovarian hemangiopericytoma, 729
- Ovarian hemorrhage, 502
- Ovarian hilus cells, 459-463
- Ovarian hyperstimulation syndrome, 485
- Ovarian hyperthecosis, 489

- Ovarian leiomyoma, 724–725
 Ovarian leiomyosarcoma, 725
 Ovarian ligament, 438
 Ovarian lymphangioma, 729
 Ovarian lymphangiosarcoma, 729
 Ovarian malakoplakia, 475
 Ovarian mass, uterus-like, 473
 Ovarian mesothelial proliferation, 480
 Ovarian metastases, 742–744
 Ovarian myxoma, 724
 Ovarian neurilemmoma, 731
 Ovarian neurofibroma, 731
 Ovarian neurofibrosarcoma, 731
 Ovarian pheochromocytoma, 731
 Ovarian pregnancy, 422
 Ovarian remnant syndrome, 472–473
 Ovarian rhabdomyoma, 725
 Ovarian rhabdomyosarcoma, 725–727
 Ovarian sarcoidosis, 478
 Ovarian schistosomiasis, 476
 Ovarian seminoma, 661
 Ovarian stroma, 441–444
 androgens and, 444
 Ovarian stromal hyperplasia, 489
 Ovarian stromal metaplasias, 498–499
 Ovarian teratoma, 686; *see also* Germ cell tumors
 Ovarian torsion, 502–503
 Ovarian transplantation, animal, 903–904
 Ovarian tuberculosis, 475
 Ovarian tumors
 adenomatoid, 732
 in animals, 900–902
 associated with carcinoid syndrome, 646
 associated with paraendocrine disorders, 646–649
 associated with paraneoplastic syndromes, 649–650
 associated with thyroid hyperfunction, 646
 associated with Zollinger–Ellison syndrome, 649
 bovine, 900–901
 canine, 901
 carcinoid, *see* Carcinoid tumors connective tissue disorders and, 649
 disseminated intravascular coagulation (DIC) and, 650
 with endocrine function, 643–646
 epithelial, *see* Epithelial tumors of ovary
 equine, 901
 feline, 901
 fowl, 901
 with functioning stroma, 643–646
 germ cell, *see* Germ cell tumors of ovary
 giant cell, 731
 hematologic disorders and, 649–650
 hypercalcemia and, 647
 hypoglycemia and, 649
 induction of, in animals, 902–907
 mesenchymal, nonspecific to ovary, 722–733
 metastatic, 742–762
 mixed mesodermal, 582–586
 nervous system disorders and, 649
 nonspecific, 722–740
 primate, 901
 of probable wolffian origin, 738–740
 rodent, 901
 sex cord-stromal, *see* Sex-cord stromal ovarian tumors
 swine, 901
 Ovarian vasoligation, rat, 904
 Ovarian vein syndrome, 503
 Ovarian vein thrombophlebitis, puerperal, 503
 Ovarian veins, 439, 503
 Ovary
 absent, 471–472
 accessory, 472
 actinomycosis of, 475
 in adulthood, 438–463
 anatomy and histology of, 438–466
 animal, as experimental model, 902
 blood vessels of, 438–439
 bone within, 499
 carcinoid tumors of, *see* Carcinoid tumors
 carcinoma of, FIGO staging of, 563
 changes secondary to cytotoxic drugs and radiation of, 503–504
 changes secondary to metabolic diseases of, 503
 in childhood, 463–464
 congenital lesions of, 471–473
 disorders of premature failure of, 499–502
 fat within, 499
 fungal infections of, 477
 granulomas of, 477–478
 gross anatomy of, 438–440
 hemangioendothelial sarcoma of, 728–729
 Hodgkin's disease localized to, 735
 infectious diseases of, 473–477
 inflammatory disorders of, 473–478
 involvement of, by leukemia, 737–738
 lobulated, 472
 lymphatics of, 439–440
 in menopause, 464–466
 nerve supply of, 440
 of newborn, 463–464
 noninfectious diseases of, 477–478
 nonneoplastic lesions of, 471–504
 oophorectomy, tissue processing of, 936–937
 parasitic infestations of, 476
 radiation and, 504
 supernumerary, 472
 surface epithelium of, 440–441
 surface proliferative lesions of, 478–480
 tumors of, *see* Ovarian tumors
 vascular lesions of, 502–503
 xanthogranuloma of, 474
 Ovary disease, polycystic (PCO), 486–489, 896–897
 Ovary syndrome, resistant, 501
 Ovotestis, 33
 Ovulation, 447–448
 morphologic evidence of, 267
 Ovulatory smear pattern, 895
 Ovum, 1, 769
 blighted, 853
 Paget cells, 71
 Paget's disease, vulvar, 70–71
 Palisading granulomas, isolated, ovary, 477–478
 Pancreas, tumors, metastatic to ovary, 758–759
 Paneth cells, 238
 Papillary adenofibroma, of cervix, 170–171
 Papillary carcinoma, of endometrium, 345
 Papillary endometrioid carcinoma, of ovary, 581
 Papillary hidradenoma, 63–64
 Papillary lesions, multiple extraovarian, 601
 Papillary mesothelioma, well-differentiated, 548
 Papillary metaplasia, of endometrium, 329, 330
 Papilloma, squamous, 65
 Papillomatosis, 189
 Papillomavirus infection, human, *see* Human papillomavirus infection
 PAPP-A (pregnancy-associated plasma protein A), 773
 Parabasal cells, 143, 876, 877
 Parabiosis, 905
 Paraendocrine disorders, ovarian tumors associated with, 646–649
 Parakeratosis, cervical, 159, 161
 Paramesonephric duct, *see* Müllerian ducts
 Paraneoplastic syndromes, ovarian tumors associated with, 649–650
 Paraovarian cysts, 413
 Paraovarian tumor, 431
 Parasitic cervicitis, 165
 Parasitic oophoritis, 476
 Parasitic salpingitis, 419
 Parasitic vaginitis, 105
 Paratubal cysts, 431–432

- Paratubal tumors, 430-431
 Parvilocular tumors, 587
 PAS (periodic acid-Schiff) reaction, 240, 351, 353, 663
 PCO (polycystic ovary disease), 486-489, 896-897
 Peg cells, 411
 Pelvic actinomycosis, 474-475
 Pelvic exenteration, processing of specimen, 931
 Pelvic inflammatory disease (PID), 414-417, 473-474
 involving endometriosis, 524
 Pelvic lymph nodes, endosalpingiotic glands within, 542-544
 leiomyomatosis, 544
 Pelvic mesothelial proliferations, 545-548
 Pelvic peritoneal endometriosis, 519-528
 Pelvis, sagittal section through, 933
 Pemphigoid, 50
 Pemphigus, familial benign, 51-52
 Pericytes, 403
 Perinatal mortality, 781-782
 Periodic acid-Schiff (PAS) reaction, 240, 351, 353, 663
 Peritoneal cytology, 364, 894
 Peritoneal defects, 519
 Peritoneal endometrioid lesions, 540
 Peritoneal endometriosis, pelvic, 519-528
 Peritoneal fluid macrophages, 527-528
 Peritoneal gliomatosis, 524, 689
 Peritoneal inclusion cysts, 546-547
 Peritoneal leiomyomatosis, disseminated, 383-384
 Peritoneal mesothelioma, 732-733
 well-differentiated papillary, 548
 Peritoneal mucinous lesions, 539-540
 Peritoneal papillary and glandular lesions, extraovarian, 536-540, 601
 Peritoneal serous lesions, 536
 Peritoneal serous tumors, 539
 Peritoneal transitional cell lesions, 540-541
 Perivillous fibrin deposition, 798-799
 Perivitelline space, 449
 Peutz-Jeghers syndrome, 242, 636, 637
 Pflügerome, 709
 Pheochromocytoma, ovarian, 731
 Picket cells, 146
 PID, *see* Pelvic inflammatory disease
 Pigmentosa tubae, 411
 Pinworms, 49, 419
 Pituitary growth hormone in animals, 911
 Pituitary isografts in animals, 911
 Placenta
 abnormalities of implantation of, 777-779
 abnormalities of shape, 775-776
 accessory lobe of, 775, 776
 anatomy and circulation of, 773
 ascending infection in, 784-789
 bilobate, 775-776
 bipartite, 775-776
 chorioamnionitis, 784-789
 choriocarcinoma arising in, 862
 circulatory disorders of, 796-803
 circummarginate, 777
 circumvallate, 777
 development of, 769-773
 in diabetes mellitus, 806-807
 dichorionic, 939
 in essential hypertension, 806
 fenestrate, 776
 in fetal disorders, 803-809
 gross structural abnormalities of, 776-777
 hematogenous infections of, 789-790
 infarct in, *see* Infarct in placenta
 in maternal disorders, 803-809
 maturation of, 773-774
 multilobate, 776
 in multiple pregnancy, 779-784
 nontrophoblastic tumors of, 823-827
 pathology of membranes of, 809-812
 physiology of, 774-775
 in preeclampsia, 803-806
 ring-shaped, 776
 sickle-cell trait and, 807
 succenturiate lobe of, 775-776
 twin, 779, 781-782
 processing method, 939
 Placenta accreta, 777-778
 Placenta extrachorialis, 776-777
 Placenta increta, 777
 Placenta membranacea, 776
 Placenta percreta, 777, 779
 Placenta previa, 778
 Placental abruption, 801
 Placental alkaline phosphatase (PLAP), 480, 667, 853
 Placental examination, 937-940
 Placental hemangioma, 823-825
 Placental inflammation, 784-796
 Placental lactogen, human (hPL), 480, 773, 845, 847, 848, 849
 Placental metastases, 823-825
 from breast carcinoma, 826
 from malignant melanoma, 825
 from neuroblastoma, 827
 Placental origin, tumors of, in animals, 908-909
 Placental protein 5 (PP5), 868
 Placental site reaction, 283, 836
 Placental site trophoblastic tumor (PSTT), 836, 862-868
 Placental teratoma, 825
 Placental tumor induction in animals, 908-909
 Placentitis, CMV, 790-792
 PLAP (placental alkaline phosphatase), 480, 667, 853
 Plasma cell dyscrasia, involvement of ovary, 738
 Plasma cells, in diagnosis of chronic endometritis, 295
 Pleomorphic rhabdomyosarcoma, 726
 Pleuropulmonary endometriosis, 533
 Plexiform leiomyoma, 377-379
 Plexiform tumorlets, 379
 Pneumopolycystic endometritis, 298
 Pneumothorax, secondary to pleuropulmonary endometriosis, 533
 Podophyllin effect, 41, 42
 Polycystic ovary disease (PCO), 486-489, 896-897
 Polycybryoma, 682-684
 Polypoid adenomyoma, atypical, 307-309, 401-402
 Polyvesicular vitelline tumor pattern of endodermal sinus tumor, 673-675
 Portio epithelium, 142-145
 Posterior fornix aspiration, 897
 Postirradiation dysplasia, 251
 Postmenopausal bleeding, *see* Bleeding
 Postmenopausal vaginal smear, 896
 Postsalpingectomy endometriosis, 530, 531
 PP5 (placental protein 5), 868
 Preantral follicles, 446, 447
 Precocity, isosexual, 616
 Predecidualization, stromal, 270-271
 Preeclampsia, 800-801, 803-806, 846
 Pregnancy
 carcinoma in, 235
 cervix in, 155-156
 chorioamnionitis and, 789
 cornual, 422
 corpus luteum of, 455-457
 destruction of hypothalamic nucleus in animals during, 909
 documentation of, 817
 ectopic, 421-423
 endometriosis and, 526
 hyperreactio luteinalis, 484
 intramural, 421
 large solitary luteinized follicle cysts of, 483
 luteoma, 495-497, 642
 multiple, 779-784
 ovarian, 422
 rubella infection during, 791-793
 sex cord-stromal tumors during, 637-638
 toxemia of, 803; *see also* Preeclampsia
 tubal, 421
 tumors with functioning stroma occurring during, 645
 vaginal smear in, 896

- Pregnancy-associated plasma protein A (PAPP-A), 773
- Pregnancy-specific beta 1-glycoprotein (SP₁), 773, 868
- Premature menopause, 500-501
- Premature ovarian failure, 499-502
- Prematurity, ovarian changes associated with, 485
- Premenarcheal vaginal smear, 895
- Preovulatory endometrium, 262-264
- Primate ovarian tumors, 901
- Primitive streak, 2
- Primordial follicles, 444-446
- Prochordal plate, 2
- Progestagens in animals, 905
- Progesterone
 - cytologic changes associated with, 894
 - in animals, 911, 914
 - endometrial cycle and, 260-261
 - ovary, 451, 454-455
- Progesterone receptors, 260-261
 - endometrial carcinoma and, 360-361
 - endometriosis and, 525
- Progestins
 - endometrial carcinoma and, 366-367
 - endometriosis and, 524
 - endometrium and, 311
 - masculinization of female infants associated with maternal ingestion of, 21
- Prolactin, 283, 488, 527
- Prolapse, uterine, 106
- Proliferative endometrium, 262-267
- Proliferative villitis, 790
- Prostaglandins
 - endometriosis and, 527
 - endometrium and, 314
- Protozoal cervicitis, 165
- Psammoma bodies, 238, 411, 412, 479, 537, 538, 564, 893
- Pseudohermaphroditism
 - female, 20-22
 - male, 22-26
- Pseudomalignant stromal atypia, associated with oral contraceptives, 312
- Pseudomyxoma peritonei, 577-578
- Pseudopolyp, 128
- Pseudoprecocity, 616
- Pseudosarcoma, associated with oral contraceptives, 312
- Pseudotumor
 - trophoblastic, *see* Placental site trophoblastic tumor
 - of uterus, 403-404
- Pseudoxanthoma cells, 521
- Psoriasis, 52
- PSTT, *see* Placental site trophoblastic tumor
- Pudendal arteries, 38
- Puerperal ovarian vein thrombophlebitis, 503
- Puerperium
 - cervix in, 155-156
 - hyperreactio luteinalis in, 484
 - large solitary luteinized follicle cysts of, 483
- Punch biopsy, cervical, 204, 927
- Pyoderma gangrenosum, 49
- Pyogenic granuloma, 59-60
- Quantitative cytomorphology, 332-333
- Radiation
 - of animals, 905-906, 913
 - in cervical cancer, 233-234
 - cytologic changes of, 890
 - effects, on cervix, 248-251
 - in endometrial cancer, 364
 - endometrial carcinoma and histologic effects of, 365-366
 - ovarian changes secondary to, 504
- Radiotherapy, *see* Radiation
- Rapid plasma reagin (RPR) test, 45
- Rectosigmoid, endometriosis of, 528
- Regan isoenzyme, 667
- Reifenstein's syndrome, 25-26
- Reinke crystals, 430, 460-461, 639-641
- Relaxin, 272, 457
- Renal cell carcinoma, metastatic to ovary, 759-760
- Renal endometriosis, 531
- Renin-producing Sertoli cell tumors, 649
- Reparative villitis, 790
- Reserve cells, subcolumnar, 153-154
- Resistant ovary syndrome, 501
- Rete ovarii, 6-7, 463
- Retroperitoneal hemorrhage, 503
- Retroperitoneal mucinous cystadenocarcinoma, 539, 540
- Retroperitoneal mucinous tumor, 539
- Retroplacental hematoma, 800-801
- Rhabdomyoma
 - of ovary, 725
 - of vagina, 109-110
 - of vulva, 60
- Rhabdomyosarcoma
 - embryonal, 114-116
 - of ovary, 725-727
 - of uterus, 400
 - of vagina, 116-117
 - of vulva, 81
- Rhesus (Rh) incompatibility, materno-fetal, 807-809
- Ring-shaped placenta, 776
- Rodent ovarian tumors, 901
- Rokitansky-Kuster-Hauser syndrome, 294
- Rokitansky's protuberance, 691
- Round cell tumors, undifferentiated
 - small, 727
- Rubella infection during pregnancy, 791-793
- Salpingectomy, tissue processing, *see* Gynecologic and obstetric specimens
- Salpingitis, 414-421
 - actinomycotic, 418-419
 - acute, 414-415
 - chronic, 415-417
 - endometriosis and, 524
 - foreign body, 419-420
 - granulomatous, 417-420
 - parasitic, 419
 - tuberculous, 418
- Salpingitis follicularis, 416
- Salpingitis isthmica nodosa, 420-421, 536
- Salpingo-oophorectomy, bilateral, tissue processing, *see* Gynecologic and obstetric specimens
- Sarcoid, 419, 478
- Sarcoidosis, 297
- Sarcoma, *see also* specific sites
 - alveolar soft part, 117
 - in endometriosis, 534
 - hemangioendothelial, of ovary, 728-729
 - Kaposi's, 81-82
 - metastatic to ovary, 762
 - ovarian granulocytic, 737
 - stromal, *see* Stromal sarcoma
 - synovial-like, 117-118, 119
 - undifferentiated, 733
 - uterine, 745-746; *see also* Mesenchymal tumors of uterus
 - veneral, of dog, 916
 - vulvar, *see* Vulvar sarcoma
- Sarcoma botryoides, 114-116
- Schiller-Duval bodies, 672, 673
- Schiller test, in cervix, 203, 206
- Schistosomiasis
 - cervical, 165, 166
 - endometrial, 298
 - in fallopian tube, 419
 - ovarian, 476
 - vulvar, 49
- Schwannoma, 61-62, 731
- Sclerosing stromal tumor, of ovary, 623-624
- Seatworms, 49
- Seborrheic keratosis, 66
- Secretory carcinoma, of endometrium, 346-347
- Seminoma, ovarian, 661
- Serous carcinoma
 - of endometrium, 345, 352-353
 - of low malignant potential (LMP), 569-571
 - of ovary, 571-572
- Serous cystadenofibroma, 562-567
- Serous malignant, 572-573
 - proliferating, 568, 569
- Serous cystadenoma, 561-562
- Serous lesions, peritoneal, 536

- Serous neoplasia, extraovarian, 539
- Serous tumors, 561-573
 benign, 561-569
 malignant, 569-573
 peritoneal, 539
- Sertoli cell tumors, 625-626
 lipid-rich, 625
 renin-producing, 649
- Sertoli cells, embryologic development of, 4, 6
- Sertoli-Leydig cell tumors, 625, 626-634
 adult granulosa cell tumors versus, 634
- Sertoli-stromal cell tumors, 625-634
- Sex chromatin bodies, 661
- Sex chromosomes, 15
 intersex disorders associated with abnormal, 26-33
 intersex disorders associated with normal, 20-26
- Sex cord-mesenchyme tumors of ovary, 608
- Sex cord-stromal tumors of ovary, 607-639
 immunohistochemistry of, 638-639
 other types of, 634-638
 during pregnancy, 637-638
 unclassified, 608, 636, 637
 uterine neoplasm resembling, 392-393
- Sex cord tumor with annular tubules, 635-636, 637
- Sex cords, embryologic development of, 4, 6
- Sex steroids, biosynthesis of, 20
- Sexual development
 abnormal, disorders of, 15-33
 embryology of, 15-20
- Sickle-cell trait, placenta in, 807
- Signet-ring cell carcinoma, metastatic to ovary, 748
- Signet ring stromal tumor, of ovary, 624
- Skin tags, 63
- Small cell carcinoma of cervix, 245-248
 granulosa cell tumors versus, 617
 of ovary, hypercalcemia and, 647-648
- Small round cell tumors, undifferentiated, of ovary, 727
- Smooth muscle
 in endometriosis, 523
 in endometrium, 310
 in lymph nodes, 544
 in ovary, 442, 499
 peritoneal, 542
- Smooth muscle tumors, 374-386
 of uncertain malignant potential, 385
- Solid adult teratoma, 688
- Solid mature (benign) teratoma, 688-690
- Southern blot hybridization, 181
- SP₁ (pregnancy-specific beta 1-glycoprotein), 773, 868
- Spermatozoa, 413, 879
- Spermatozoal penetration in animals, 916
- Spiral arteries, 286, 771-772
- Spiral arterioles, 259
- Splenic-gonadal fusion, 473
- Splenosis, 524
- Spontaneous abortion, 528, 816-817
 abnormal karyotypes in, 820
 endometriosis and, 528
 implantation site of, 819
 morphologic correlations in, 818-823
- Spontaneous choriocarcinoma in animals, 908
- Spontaneous teratoma in animals, 907-908
- Squamocolumnar junction of cervix, 147-151
- Squamous carcinoma adenoid, 78
 of cervix, 224-235
 cytology of, 887, 889
 of uterus, 354
 of vagina, 113-114
 of vulva, 71-77
- Squamous differentiation, adenocarcinoma with, 348-351, 580
- Squamous epithelium, cervical, 142-145
- Squamous hyperplasia, vulva, 56-57
- Squamous metaplasia, 152-153, 326-328
 adenocarcinoma with, 348-350
 of amnion, 809
 in endometriosis, 523
 of intranodal glands, 543
- Squamous papilloma, 65
- Squamous prosoplasia, 152
- Staining tests, cervix, 203
- Starry sky appearance, in Burkitt's lymphoma, 736-737
- Stein-Leventhal syndrome, 299, 896-897
- Sterilization, salpingectomy for, 935-936
- Steroid cell tumors, 639-642
 of adrenal cortical type, 641
 not otherwise specified, 641-642
 stromal tumors versus, 624
- Strawberry hemangioma, 59
- Stroma
 endometrial, 283, 285
 functioning
 ovarian tumors with, 643-646
 tumors with, occurring during pregnancy, 645
- Stromal atrophy, of ovary, 465
- Stromal cells, 442-443
 enzymatically active, 442, 597
 luteinized, 643
- Stromal granulocytes, 294
- Stromal hyperplasia, 331-332, 489-491
- Stromal hyperthecosis, 489-491, 639
- Stromal invasion
 depth of, in cervical carcinoma, 219
 endometrial, 340-344
- Stromal Leydig cell hyperplasia, 498
- Stromal Leydig cell tumors, 619, 620
- Stromal luteoma, 639, 640
- Stromal metaplasias, ovarian, 498-499
- Stromal myosis, endolymphatic, 386, 389
- Stromal predecidualization, 270-271
- Stromal sarcoma
 endometrial, 388-392
 endometrioid, 534-535
 high-grade, 388-392
 low-grade, 388-391
- Stromal tumors
 sclerosing, 623-624
 signet ring, 624
 steroid cell tumors versus, 624
- Stromatosis, 388
- Stromomyoma, 392-393
- Struma ovarii, 686, 694-696
 and carcinoid, 701-703
 malignant, 696
- Strumal carcinoid, 701-703
- Subamniotic hematoma, 802-803
- Subarachnoid endometriosis, 533
- Subchorial thrombosis, massive, 799-800
- Subchorionic fibrin, 799
- Subcolumnar reserve cells, 153-154
- Submucosal leiomyoma, 375
- Subperitoneal mesenchymal lesions, 541-542
- Subserosal leiomyoma, 375
- Succenturiate lobe of placenta, 775, 776
- Sulfur granules, 163, 475
- Superficial cells, cytology of, 877
- Supernumerary ovary, 472
- Surface stromal proliferations, of ovary, 480
- Sweat gland carcinoma, of vulva, 80-81
- Swine ovarian tumors, 901
- Symphastic leiomyoma, 377
- Syncytionoma, 862
- Syncytiotrophoblast, 684-685, 769-771, 839-842, 844-845
- Syncytiotrophoblast cells
 dysgerminomas with, 643, 644
 germ cell tumors containing, 644
- Synovial-like sarcoma, 117-118, 119
- Syphilis, 44-45, 105
 congenital, 793
 ovarian, 476
- Syringoma, 64-65

- T-shaped endometrial cavity, 13
 TA-4 monoclonal antibody, 230, 232, 234
 Teillum tumor, 669
 Teratoma
 in animals, 902
 benign, 426
 benign solid, 688
 cystic, *see* Cystic teratoma
 immature, 686-688
 malignant, with embryoid bodies, 682
 mature solid, 688-690
 monodermal, 703
 ovarian, 686
 placental, 825
 solid mature, 688-690
 spontaneous, in animals, 907-908
 tubal, 426
 of uterus, 308, 309
 Teratomatous choriocarcinoma, 684
 Terminal villi, 773-774
 Testicular feminization, 12-13, 24-25
 Testicular grafts in animals, 911
 Testicular regression syndrome, 19, 22
 Testosterone, 16, 444, 463, 490-491
 defects in synthesis of, 23-24
 disordered metabolism of, 26
 elevated plasma levels of, 626
 in embryologic development, 16
 Theca layer, 450-452, 456
 Theca-lutein cells, 452-454
 Thecoma, 619-621
 luteinized, 619, 620
 Thrombohematoma, massive subchorial, 799-800
 Thrombophlebitis, puerperal ovarian vein, 503
 Thrombosis, fetal artery, 803
 Thrombus, intervillous, 802, 803
 Thymectomy, animal neonatal, 903
 Thymoma, metastatic to ovary, 761
 Thyroid hormone in animals, 905
 Thyroid hyperfunction, ovarian tumors associated with, 646
 Toluidine blue dye, in cervix, 203
 Tonofilaments, 232
 Torsion, ovarian or adnexal, 502-503
 Toxemia of pregnancy, 803; *see also* Preeclampsia
 Toxic shock syndrome, 107
 Toxoplasmosis, 298, 794-795
 Trabecular carcinoid, 698-700
 Transformation zone of cervix, 147-155
 histogenetic development of, 151-153
 Transfusion syndrome, twin-twin, 782-783
 Transitional cell lesions, peritoneal, 540-541
Treponema pallidum, 44
Treponema pallidum immobilization, 45
Trichomonas vaginalis, 105, 882, 884
 Triplets, 784
 Triploidy, 818, 820, 838-839
 Trisomy 13 fetus, 818
 Trizygotic triplets, 784
 Trophoblast, 769
 cytotrophoblast, 684-685, 769-772, 839-845
 extravillous, 839
 identification of, in curettings, 817
 intermediate, 770-773, 805, 839-843, 845-846
 morphology and immunocytochemistry of, 839-846
 syncytiotrophoblast, 684-685, 769-771, 839-842, 844-845
 villous, 839
 Trophoblastic migration, intravascular, 518, 804-805
 Trophoblastic pseudotumor, *see* Placental site trophoblastic tumor
 Trophoblastic tumor(s), metastatic to ovary, 746-747
 placental site, *see* Placental site trophoblastic tumor
 Trypsin inhibitors, 413
 Tubal adenocarcinoma, 429
 Tubal adenocarcinoma, 427-429
 Tubal bilharziasis, 419
 Tubal carcinosarcoma, 429
 Tubal endometriosis, 529-530
 Tubal fistula, postligation, 424, 530
 Tubal leiomyoma, 425
 Tubal metaplasia, in endometrium, 328-329
 Tubal pregnancy, 421
 Tubal teratoma, 426
 Tuberculosis, vulvar, 47-48
 Tuberculous cervicitis, 163
 Tuberculous endometritis, 296-297
 Tuberculous oophoritis, 475
 Tuberculous salpingitis, 418
 Tuboovarian abscess, 416, 473-474
 Tuboovarian carcinoma, 744
 Tubular Krukenberg tumors, 632
 Tumor-associated antigens, 600-601
 Tumorlets, plexiform, 379
 Tunica albuginea, 438
 Turner's syndrome, 26-28, 518
 cytology smear in, 896
 Twin gestation, 779-782
 Twin placenta, 779-784
 processing of, 939
 Twin-twin transfusion syndrome, 782-783
 Ulceronecrotic amebiasis of cervix, 165
 Umbilical artery, single, 813-815
 Umbilical cord
 cysts within, 816
 edema of, 816
 hemangioma of, 824
 hematoma of, 816
 inflammation of, 786
 insertion of, 813
 knots in, 815-816
 length of, 813
 pathology of, 812-816
 single umbilical artery in, 813-815
 torsion and stricture of, 816
 vestigial remnants of, 812-813
Ureaplasma urealyticum, 296
 Ureter tumors, 760
 Ureteral compression, 234
 Ureteric buds, 3
 Ureteric endometriosis, 531
 Urethra, lesions of, 86-87
 Urethral carcinoma, 87
 Urethral endometriosis, 531
 Urethral tumors, 760
 Urinary bladder
 endometriosis of, 531
 urothelial cells of, 594
 Urinary bladder tumors, metastatic to ovary, 760
 Urinary tract abnormalities, 13
 Urinary tract endometriosis, 530-532
 Urogenital ridge, 3-4
 Urogenital sinus, 3-4
 Urorectal septum, 12
 Urothelial cells of human urinary bladder, 594
 Uterine abnormalities, 137
 Uterine bleeding, dysfunctional, 286, 299; *see also* Bleeding
 Uterine cervix, tumors of, in animals, 913-916
 Uterine choriocarcinoma, 860-861
 Uterine corpus
 anatomy and histology of, 257-289
 tumors of, in animals, 909-913
 Uterine leiomyoma, 724
 Uterine neoplasm resembling ovarian sex cord tumor, 392-393
 Uterine prolapse, 106
 Uterine sarcoma, *see* Mesenchymal tumores of uterus; Mesodermal mixed tumors
 Uterine tumors,
 metastatic to ovary, 745-747
 Uteroovarian ligament, 438
 Uterotubal junction, 409
 Uterus, 932
 anatomy of, 257
 angiosarcoma in, 403
 bivalve opening of, 934
 carcinomas of, *see* Endometrial carcinoma
 congenital abnormalities of, 292-294

- Uterus (*cont.*)
 glioma of, 310
 hemangioma in, 402-403
 hysterectomy, processing of, 931-935
 mesenchymal tumors of, *see* Mesenchymal tumors of uterus
 pseudotumor of, 403-404
 residual carcinoma in, 335-336
 teratomas of, 308, 309
 vascular anatomy of, 258-260
 Uterus bicornis unicollis, 293-294
 Uterus-like mass, 473, 523
- Vaccinia, genital, 884
- Vagina
 anatomy of, 98
 arterial blood supply of, 102
 atresia of, 293-294
 benign tumors and tumor-like condition of, 108-111
 carcinoma, *see* Vaginal carcinoma
 congenital anomalies of, 103-104
 cysts of, 104
 diseases of, 97-137
 endometriosis, 529
 epithelial tumors of, 113-114
 gross structural changes of, 128
 in utero DES exposure, lesions associated with, 121-137
 infectious diseases of, 104-106
 inflammatory disorders of, 104-107
 lymphatic drainage of, 101-103
 melanoma of, 118-119, 120-121
 metastatic tumors of, 119
 mixed tumor of, 109-110
 mucosa of, 98-101
 noninfectious diseases of, 106-107
 nonneoplastic changes of, 128-134
 preneoplastic changes of, 134-135
 sarcomas of, 114-118
 squamous carcinoma of, 113-114
 structural relationships of, 98
 tumors of, in animals, 913-916
 vascular and nerve supply of, 99, 101
 venous drainage of, 102
 Vaginal adenosis, 104, 129-130
 embryologic basis of, 131-134
 Vaginal biopsy, tissue processing of, 927
 Vaginal candidiasis, 105
 Vaginal carcinoma
 adenocarcinoma, 114
 in situ, 111-112
 metastatic to ovary, 747
 squamous, 113-114
 basal cell, 114
 verrucous, 114
 Vaginal endometriosis, 529
 Vaginal epithelial changes (VEC), 128, 130
- Vaginal intraepithelial neoplasia (VAIN), 111-113
 Vaginal plate, 8, 10
 Vaginal polyps, 108
 Vaginal septum, transverse, 103-104
 Vaginal smear, 894, 895-896
 method of obtaining, 897
 postmenopausal, 896
 in pregnancy, 896
 premenarcheal, 895
 Vaginectomy, tissue processing of, 931
 Vaginitis, 882
 emphysematous, 107
 herpes, 883, 885
 parasitic, 105
 Vaginosis, bacterial, 105
 VAIN (vaginal intraepithelial neoplasia), 111-113
 Vascular alterations, endometrial, during menstrual cycle, 259
 Vascular invasion, 218-220, 363
 Vascular leiomyoma, 380
 Vascular polyp, 167
 Vascular spaces, term, 222
 VDRL (Venereal Disease Research Laboratory) test, 45
 VEC (vaginal epithelial changes), 128, 130
 Velamentous insertion of umbilical cord, 813
 Venereal Disease Research Laboratory (VDRL) test, 45
 Venereal sarcoma of dog, 916
 Verrucous carcinoma
 of cervix, 235-236
 of vagina, 114
 of vulva, 78-79
 Vestibulitis, 37, 38
 vulvar, 52
 Villi, terminal, 773-774
 Villitis, 790
 cytomegalovirus infection, 790-792
 of unknown etiology, 795-796
 Villous edema, 821, 823
 Villous trophoblast, 839
 Vimentin, 441, 598, 599
 VIN (vaginal intraepithelial neoplasia), *see* Vulvar tumors, intraepithelial neoplasia
 Viral cervicitis, 163-165
 Viral oophoritis, 476
 Virilization, 626
 Virilizing tumors, maternal, 21-22
 Vitamin B₁₂ deficiency, cytologic changes associated with, 881
 Vitiligo, 52
 Vulva
 adenocarcinoma of, *see* Vulvar carcinoma
 anatomy of, 36-39
 developmental defects of, 39
 diseases of, 36-87
 Donovan bodies, 46
 dystrophic conditions of, 54-57
 ectopic breast tissue in, 63
 hyperpigmented lesions of, 52-54
 hypopigmented conditions of, 52
 infectious diseases of, 39-49
 inflammatory diseases of, 39-52
 lymphatics of, 39, 931
 melanomas of, 83-85
 noninfectious diseases of, 49-52
 pigmentation disorders of, 52-54
 sarcomas of, 81-82
 tumors of, *see* Vulvar tumors
 Vulvar biopsy, 927
 Vulvar carcinoma, 71-81
 adenocarcinoma, 79-81
 Bartholin's gland, 80
 sweat gland, 80-81
 metastatic to ovary, 747
 squamous, 71-79
 adenoid, 78
 basal cell, 79
 superficially invasive, 74-77
 verrucous, 78-79
 Vulvar dystrophy, hyperplastic, 56-57
 Vulvar endometriomas, 63, 532
 Vulvar intraepithelial neoplasia (VIN), 41-42, 66-70
 Vulvar Paget's disease, 70-71
 Vulvar sarcoma, 81-82
 alveolar soft part, 82
 dermatofibrosarcoma protuberans, 81
 epithelioid, 81
 Kaposi's 81-82
 leiomyosarcoma, 81
 malignant fibrous histiocytoma, 81
 rhabdomyosarcoma, 81
 Vulvar schistosomiasis, 49
 Vulvar tuberculosis, 47-48
 Vulvar tumors
 adenocarcinoma, 79-81
 in animals, 913-916
 benign cystic, 57-59
 benign solid, 59-66
 carcinoma in situ, *see* Vulvar tumors, intraepithelial neoplasia
 dysplasia, *see* Vulvar tumors, intraepithelial neoplasia
 endodermal sinus, 85
 epithelial, 63-66
 intraepithelial neoplasia (VIN), 41-42, 66-70
 melanoma, 83-85
 mesenchymal, 59-63
 metastatic, 85-86
 Paget's disease, 70-71
 sarcomas, 81-82
 squamous carcinoma, 71-74
 adenoid, 78
 basal cell, 79

- superficially invasive, 74-77
verrucous, 78-79
Vulvar ulcer, acute idiopathic, 50
Vulvar vestibulitis, 52
Vulvectomy, processing tissue from, 928-931
- Walthard nests, 424, 425, 483, 540-541, 589
Wharton's jelly, 812
- Winter syndrome, 294
Wolffian duct, 8-11, 17-19
 cysts of, 59
Wolffian origin, adnexal tumor of probable, 430-431, 738-740
- X cells, 773
Xanthogranulomatous oophoritis, 474
XX male syndrome, 28
- Yolk sac tumors, 669; *see also* Endodermal sinus tumor
 induction of, in animals, 908
- Z-bands, 726
Zollinger-Ellison syndrome, ovarian tumors associated with, 646
Zona pellucida, 413
 oocytes and, 448-449

